ConductScience.org, home

Paper6239686

Immunomodulation and therapeutic characterization of thymosin fraction five.

Talmadge JE and 3 others. Cancer Immunol Immunother, 1984. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Immunomodulation and therapeutic characterization of thymosin fraction five. Papers, record 6239686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6239686

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunomodulation and therapeutic characterization of thymosin fraction five.
PubMed
Journal
Cancer Immunol Immunother
PubMed
Year
1984
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.33
iCite
Revised in PubMed
2024-04-26
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Talmadge JEJ E
2Uithoven KAK A
3Lenz BFB F
4Chirigos MM

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
FibrosarcomaMajor topic
Leukemia, ExperimentalMajor topic
MelanomaMajor topic
Neoplasms, Radiation-InducedMajor topic
T-LymphocytesMajor topic
ThymosinMajor topic
Animals
Cell Line
Immunotherapy
Lymphocyte Culture Test, Mixed
Male
Mice
Mice, Inbred C3H
Mice, Inbred C57BL
Neoplasm Metastasis
Ultraviolet Rays

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
N01-CO-23910NCI NIH HHSUnited StatesN01CO023910PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16707701Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers.J Biol Response Mod1984https://conductscience.org/library/papers/6707701PubMed
26232241The effect of experimental conditions on the assessment of T cell immunomodulation by biological response modifiers (thymosin fraction five).Immunopharmacology1984https://conductscience.org/library/papers/6232241PubMed
36214350Thymosin modulation of regulatory T cell function.Clin Immunol Immunopathol1982https://conductscience.org/library/papers/6214350PubMed
4216684The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus.J Biol Chem1979https://conductscience.org/library/papers/216684PubMed
6305674Thymosin treatment of children with primary immunodeficiency disease.Transplant Proc1978https://conductscience.org/library/papers/305674PubMed
76972536Induction of terminal deoxynucleotidyl transferase and Lyt antigens with thymosin: identification of multiple subsets of prothymocytes in mouse bone marrow and spleen.Proc Natl Acad Sci U S A1981https://conductscience.org/library/papers/6972536PubMed
8141974The effect of thymosin on patients with disseminated malignancies. A phase I study.Cancer1977https://conductscience.org/library/papers/141974PubMed
96804089Resistance to L1210 mouse leukemia cells in moderately protein-malnourished BALB/c mice treated in vivo with thymosin fraction V.Cancer Res1982https://conductscience.org/library/papers/6804089PubMed
10316979Effects of thymosin in vitro in cancer patients and correlation with clinical course after thymosin immunotherapy.Ann N Y Acad Sci1979https://conductscience.org/library/papers/316979PubMed
116450736Regulation of in vitro generation of cell-mediated cytotoxicity. II. Characterization of thymosin-induced suppressor T cells.Immunopharmacology1980https://conductscience.org/library/papers/6450736PubMed
124551691Immune responses in vitro. I. Culture conditions for antibody synthesis.Cell Immunol1972https://conductscience.org/library/papers/4551691PubMed
137365733Tumor cytotoxicity of rat alveolar macrophages activated in vitro by endotoxin.J Reticuloendothel Soc1980https://conductscience.org/library/papers/7365733PubMed
1414130672ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT.J Natl Cancer Inst1964https://conductscience.org/library/papers/14130672PubMed
15679204Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin.Cancer Res1978https://conductscience.org/library/papers/679204PubMed
166161188In vivo generation of suppressor T cells by thymosin in congenitally athymic nude mice.J Immunol1981https://conductscience.org/library/papers/6161188PubMed
17236717Purification and properties of bovine thymosin.Ann N Y Acad Sci1975https://conductscience.org/library/papers/236717PubMed
18310343Thymosin-inducible lymphocytes in the peripheral blood of patients with malignant melanoma.Cancer Treat Rep1978https://conductscience.org/library/papers/310343PubMed
19165764Thymosin-induced differentiation of murine thymocytes in allogeneic mixed lymphocyte cultures.Ann N Y Acad Sci1975https://conductscience.org/library/papers/165764PubMed
20507192The selection and characterization of an invasive variant of the B16 melanoma.Am J Pathol1979https://conductscience.org/library/papers/507192PubMed
214645593Immune responses in vitro. V. Role of mercaptoethanol in the mixed-leukocyte reaction.Cell Immunol1972https://conductscience.org/library/papers/4645593PubMed

See all 33 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
27450735Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?Vitam Horm2016https://conductscience.org/library/papers/27450735PubMed
3879016Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.Springer Semin Immunopathol1985https://conductscience.org/library/papers/3879016PubMed
3543534Thymosins and anti-thymosins: properties and clinical applications.Med Oncol Tumor Pharmacother1986https://conductscience.org/library/papers/3543534PubMed
3014672Thymic hormones--a clinical update.Springer Semin Immunopathol1986https://conductscience.org/library/papers/3014672PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6239686

GET https://conductscience.org/api/papers/v1/6239686/references?page=2